{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:01:26Z","timestamp":1780362086562,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110076","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:03:15Z","timestamp":1780358595000},"source":"Crossref","is-referenced-by-count":0,"title":["First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression"],"prefix":"10.7759","author":[{"given":"Harim I","family":"Ok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaswitha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Batheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Manalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Foroobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Yanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneeta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partam","family":"Manalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-022-02386-9","article-title":"Prevalence and correlates of perinatal depression","volume":"58","author":"Al-Abri K","year":"2023","unstructured":"Al-Abri K, Edge D, Armitage CJ. Prevalence and correlates of perinatal depression. Soc Psychiatry Psychiatr Epidemiol. 2023, 58:1581-90. 10.1007\/s00127-022-02386-9","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4397","article-title":"Brexanolone to treat postpartum depression in adult women","volume":"51","author":"Cornett EM","year":"2021","unstructured":"Cornett EM, Rando L, Labb\u00e9 AM, et al.. Brexanolone to treat postpartum depression in adult women. Psychopharmacol Bull. 2021, 51:115-30. 10.64719\/pb.4397","journal-title":"Psychopharmacol Bull"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis KM","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, et al.. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023, 180:668-75. 10.1176\/appi.ajp.20220785","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus AL","year":"2020","unstructured":"Althaus AL, Ackley MA, Belfort GM, et al.. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology. 2020, 181:108333. 10.1016\/j.neuropharm.2020.108333","journal-title":"Neuropharmacology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-24-08608.2003","article-title":"Sedation and anesthesia mediated by distinct GABAA receptor isoforms","volume":"23","author":"Reynolds DS","year":"2003","unstructured":"Reynolds DS, Rosahl TW, Cirone J, et al.. Sedation and anesthesia mediated by distinct GABAA receptor isoforms. J Neurosci. 2003, 23:8608-17. 10.1523\/JNEUROSCI.23-24-08608.2003","journal-title":"J Neurosci"},{"key":"ref6","article-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)","author":"American Psychiatry Association","year":"2022","unstructured":"American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)\r\n. American Psychiatric Association Publishing, Arlington, VA; 2022."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2011.03.009","article-title":"A meta-analysis of treatments for perinatal depression","volume":"31","author":"Sockol LE","year":"2011","unstructured":"Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev. 2011, 31:839-49. 10.1016\/j.cpr.2011.03.009","journal-title":"Clin Psychol Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1049731505282202","article-title":"Treating depression during pregnancy and the postpartum: a preliminary meta-analysis","volume":"16","author":"Bledsoe SE","year":"2006","unstructured":"Bledsoe SE, Grote NK. Treating depression during pregnancy and the postpartum: a preliminary meta-analysis. Res Social Work Prac. 2006, 16:109-20. 10.1177\/1049731505282202","journal-title":"Res Social Work Prac"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013560.pub2","article-title":"Antidepressant treatment for postnatal depression","volume":"2","author":"Brown JV","year":"2021","unstructured":"Brown JV, Wilson CA, Ayre K, et al.. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev. 2021, 2:CD013560. 10.1002\/14651858.CD013560.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15533","article-title":"Psychotropic medication in pregnancy and lactation and early development of exposed children","volume":"89","author":"Leutritz AL","year":"2023","unstructured":"Leutritz AL, van Braam L, Preis K, et al.. Psychotropic medication in pregnancy and lactation and early development of exposed children. Br J Clin Pharmacol. 2023, 89:737-50. 10.1111\/bcp.15533","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7085.932","article-title":"A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression","volume":"314","author":"Appleby L","year":"1997","unstructured":"Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ. 1997, 314:932-6. 10.1136\/bmj.314.7085.932","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v69n0420","article-title":"Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine","volume":"69","author":"Yonkers KA","year":"2008","unstructured":"Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008, 69:659-65. 10.4088\/jcp.v69n0420","journal-title":"J Clin Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-021-03600-3","article-title":"Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis","volume":"21","author":"Lee HJ","year":"2021","unstructured":"Lee HJ, Kim SM, Kwon JY. Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis. BMC Pregnancy Childbirth. 2021, 21:118. 10.1186\/s12884-021-03600-3","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113543","article-title":"Efficacy and safety of repetitive transcranial magnetic stimulation for peripartum depression: a meta-analysis of randomized controlled trials","volume":"294","author":"Liu C","year":"2020","unstructured":"Liu C, Pan W, Jia L, Li L, Zhang X, Ren Y, Ma X. Efficacy and safety of repetitive transcranial magnetic stimulation for peripartum depression: a meta-analysis of randomized controlled trials. Psychiatry Res. 2020, 294:113543. 10.1016\/j.psychres.2020.113543","journal-title":"Psychiatry Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02112-6","article-title":"Treatment patterns among patients with bipolar disorder in the United States: a retrospective claims database analysis","volume":"39","author":"Jain R","year":"2022","unstructured":"Jain R, Kong AM, Gillard P, Harrington A. Treatment patterns among patients with bipolar disorder in the United States: a retrospective claims database analysis. Adv Ther. 2022, 39:2578-95. 10.1007\/s12325-022-02112-6","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1999.0188","article-title":"Neurosteroids: biosynthesis and function of these novel neuromodulators","volume":"21","author":"Compagnone NA","year":"2000","unstructured":"Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol. 2000, 21:1-56. 10.1006\/frne.1999.0188","journal-title":"Front Neuroendocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2019.100788","article-title":"Neurosteroids as regulators of neuroinflammation","volume":"55","author":"Yilmaz C","year":"2019","unstructured":"Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, Alexaki VI. Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol. 2019, 55:100788. 10.1016\/j.yfrne.2019.100788","journal-title":"Front Neuroendocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X16662043","article-title":"Inflammasomes link vascular disease with neuroinflammation and brain disorders","volume":"36","author":"L\u00e9n\u00e1rt N","year":"2016","unstructured":"L\u00e9n\u00e1rt N, Brough D, D\u00e9nes \u00c1. Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. 2016, 36:1668-85. 10.1177\/0271678X16662043","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.143","article-title":"Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program","volume":"320","author":"Epperson CN","year":"2023","unstructured":"Epperson CN, Rubinow DR, Meltzer-Brody S, et al.. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord. 2023, 320:353-9. 10.1016\/j.jad.2022.09.143","journal-title":"J Affect Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01155-w","article-title":"Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose","volume":"61","author":"Wald J","year":"2022","unstructured":"Wald J, Henningsson A, Hanze E, Hoffmann E, Li H, Colquhoun H, Deligiannidis KM. Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose. Clin Pharmacokinet. 2022, 61:1307-19. 10.1007\/s40262-022-01155-w","journal-title":"Clin Pharmacokinet"},{"key":"ref21","unstructured":"How do brexanolone and zuranolone compare in patients with postpartum depression?. (2024). Accessed. May 1, 2026: https:\/\/dig.pharmacy.uic.edu\/faqs\/2024-2\/april-2024-faqs\/how-do-brexanolone-and-zuranolone-compare-in-patients-with-p...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19306","article-title":"Cost-effectiveness of brexanolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States","volume":"26","author":"Eldar-Lissai A","year":"2020","unstructured":"Eldar-Lissai A, Cohen JT, Meltzer-Brody S, et al.. Cost-effectiveness of brexanolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. J Manag Care Spec Pharm. 2020, 26:627-38. 10.18553\/jmcp.2020.19306","journal-title":"J Manag Care Spec Pharm"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2327946","article-title":"The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States","volume":"27","author":"O'Callaghan L","year":"2024","unstructured":"O'Callaghan L, Chertavian E, Johnson SJ, Ferries E, Deligiannidis KM. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. J Med Econ. 2024, 27:492-505. 10.1080\/13696998.2024.2327946","journal-title":"J Med Econ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABA(A) receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit A","year":"2021","unstructured":"Ghit A, Assal D, Al-Shami AS, Hussein DE. GABA(A) receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021, 19:123. 10.1186\/s43141-021-00224-0","journal-title":"J Genet Eng Biotechnol"},{"key":"ref25","unstructured":"Dailymed. ZOLOFT- sertraline hydrochloride tablet, film coated & solution, concentrate. (2023). Accessed: May 1, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fe9e8b7d-61ea-409d-84aa-3ebd79a046b5."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430123-first-reported-case-of-dissociative-symptoms-associated-with-zuranolone-use-in-peripartum-depression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:03:17Z","timestamp":1780358597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430123-first-reported-case-of-dissociative-symptoms-associated-with-zuranolone-use-in-peripartum-depression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.110076","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}